Fig. 8From: Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivoSchematic presentation of the synergistic inhibitory mechanism. In colon cancer cells, azithromycin inhibits autophagy via up-regulation of p62 and LC-3B, resulting in an increase in DR4/5, which enhances the antitumor activity of TRAIL, and ultimately augment colon cancer cell deathBack to article page